1
|
Di-Iacovo N, Ferracchiato S, Pieroni S, Scopetti D, Castelli M, Piobbico D, Pierucci L, Gargaro M, Chiasserini D, Servillo G, Della-Fazia MA. HOPS/TMUB1 Enhances Apoptosis in TP53 Mutation-Independent Setting in Human Cancers. Int J Mol Sci 2024; 25:4600. [PMID: 38731819 PMCID: PMC11083489 DOI: 10.3390/ijms25094600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2024] [Revised: 04/18/2024] [Accepted: 04/19/2024] [Indexed: 05/13/2024] Open
Abstract
TP53 mutations are prevalent in various cancers, yet the complexity of apoptotic pathway deregulation suggests the involvement of additional factors. HOPS/TMUB1 is known to extend the half-life of p53 under normal and stress conditions, implying a regulatory function. This study investigates, for the first time, the potential modulatory role of the ubiquitin-like-protein HOPS/TMUB1 in p53-mutants. A comprehensive analysis of apoptosis in the most frequent p53-mutants, R175, R248, and R273, in SKBR3, MIA PaCa2, and H1975 cells indicates that the overexpression of HOPS induces apoptosis at least equivalent to that caused by DNA damage. Immunoprecipitation assays confirm HOPS binding to p53-mutant forms. The interaction of HOPS/TMUB1 with p53-mutants strengthens its effect on the apoptotic cascade, showing a context-dependent gain or loss of function. Gene expression analysis of the MYC and TP63 genes shows that H1975 exhibit a gain-of-function profile, while SKBR3 promote apoptosis in a TP63-dependent manner. The TCGA data further corroborate HOPS/TMUB1's positive correlation with apoptotic genes BAX, BBC3, and NOXA1, underscoring its relevance in patient samples. Notably, singular TP53 mutations inadequately explain pathway dysregulation, emphasizing the need to explore additional contributing factors. These findings illuminate the intricate interplay among TP53 mutations, HOPS/TMUB1, and apoptotic pathways, providing valuable insights for targeted cancer interventions.
Collapse
Affiliation(s)
- Nicola Di-Iacovo
- Section of General Pathology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy; (N.D.-I.); (S.P.); (D.S.); (M.C.); (D.P.); (G.S.)
| | - Simona Ferracchiato
- Section of General Pathology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy; (N.D.-I.); (S.P.); (D.S.); (M.C.); (D.P.); (G.S.)
| | - Stefania Pieroni
- Section of General Pathology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy; (N.D.-I.); (S.P.); (D.S.); (M.C.); (D.P.); (G.S.)
| | - Damiano Scopetti
- Section of General Pathology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy; (N.D.-I.); (S.P.); (D.S.); (M.C.); (D.P.); (G.S.)
| | - Marilena Castelli
- Section of General Pathology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy; (N.D.-I.); (S.P.); (D.S.); (M.C.); (D.P.); (G.S.)
| | - Danilo Piobbico
- Section of General Pathology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy; (N.D.-I.); (S.P.); (D.S.); (M.C.); (D.P.); (G.S.)
| | - Luca Pierucci
- Section of General Pathology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy; (N.D.-I.); (S.P.); (D.S.); (M.C.); (D.P.); (G.S.)
| | - Marco Gargaro
- Section of Biochemical and Health Sciences, Department of Pharmaceutical Sciences, University of Perugia, 06126 Perugia, Italy;
| | - Davide Chiasserini
- Section of Physiology and Biochemistry, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy;
| | - Giuseppe Servillo
- Section of General Pathology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy; (N.D.-I.); (S.P.); (D.S.); (M.C.); (D.P.); (G.S.)
- Centro Universitario di Ricerca sulla Genomica Funzionale (C.U.R.Ge.F.), University of Perugia, 06123 Perugia, Italy
| | - Maria Agnese Della-Fazia
- Section of General Pathology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy; (N.D.-I.); (S.P.); (D.S.); (M.C.); (D.P.); (G.S.)
| |
Collapse
|
2
|
Liu Y, Cai C, Wu K, Hu L. Transmembrane and Ubiquitin-Like Domain-Containing 1 Promotes Glioma Growth and Indicates Unfavorable Prognosis. Int J Genomics 2023; 2023:3318171. [PMID: 38148953 PMCID: PMC10751162 DOI: 10.1155/2023/3318171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2023] [Revised: 12/05/2023] [Accepted: 12/08/2023] [Indexed: 12/28/2023] Open
Abstract
Background Ubiquitin-related proteins have garnered increasing attention for their roles in tumorigenesis. Transmembrane and ubiquitin-like domain-containing 1 (TMUB1) is a recently discovered protein in the ubiquitin-like domain family, yet its involvement in glioma remains poorly understood. This study is aimed at investigating the functional significance and clinical relevance of TMUB1 in glioma. Methods We conducted a comprehensive analysis using two cohorts: a retrospective glioma cohort from our hospital and The Cancer Genome Atlas (TCGA) cohort. The mRNA levels of TMUB1 were assessed through reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Clinical associations of TMUB1 in these cohorts were evaluated using correlation tests, chi-square tests, and survival analyses. Additionally, we performed TMUB1 knockdown in U87 and LN-229 human glioma cell lines, and cellular growth was assessed through the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. Results Our results revealed that TMUB1 expression was elevated in glioma tissues compared to normal brain tissues. Notably, lower TMUB1 expression correlated with favorable characteristics such as lower World Health Organization (WHO) grade and 1p/19q codeletion. Moreover, patients with higher TMUB1 levels in glioma tissues exhibited worse prognosis in both TCGA cohort and our retrospective cohort, underscoring its prognostic significance in gliomas. Cellular experiments demonstrated that TMUB1 silencing suppressed the growth of glioma cells. Conclusions TMUB1 emerges as a novel and clinically relevant prognostic biomarker for gliomas. Targeting TMUB1 holds promise as a potential strategy for glioma treatment. This study contributes valuable insights into the multifaceted role of TMUB1 in glioma pathogenesis and its potential as a diagnostic and therapeutic target.
Collapse
Affiliation(s)
- Yinggang Liu
- Department of Neurosurgery, Suining Central Hospital, Suining 629000, Sichuan, China
| | - Changcheng Cai
- Department of Neurosurgery, Suining Central Hospital, Suining 629000, Sichuan, China
| | - Ke Wu
- Department of Neurosurgery, Xichang People's Hospital, Xichang 615000, Sichuan, China
| | - Libo Hu
- Department of Neurosurgery, Suining Central Hospital, Suining 629000, Sichuan, China
| |
Collapse
|
3
|
Lu Y, Wang K, Peng Y, Zhang J, Ju Q, Xu Q, Ouyang M, He Z. TMUB1 expression is associated with the prognosis of colon cancer and immune cell infiltration. PeerJ 2023; 11:e16334. [PMID: 38025742 PMCID: PMC10658890 DOI: 10.7717/peerj.16334] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2023] [Accepted: 09/30/2023] [Indexed: 12/01/2023] Open
Abstract
Background TMUB1 is a transmembrane protein involved in biological signaling and plays an important role in the stability and transcription of P53. However, its role in tumor remains unknown. Methods Using R language, the expression level of 33 cancer spectrum TMUB1 was analyzed by the public database TCGA, GEO and HPA, the differential expressed gene (DEG) screening and protein interaction (PPI) network was constructed, and the differential genes of TMUB1 in colon cancer were identified. The relevant signaling pathways were identified by gene functional annotation and enrichment analysis. The ssGSEA algorithm in GSVA were used for immune infiltration analysis. The Kaplan-Meier analysis, univariate and multivariate Cox regression analysis, nomogram and calibration map analysis were constructed to evaluate the correlation between TMUB1 expression and clinical prognosis. The expression levels of TMUB1 in intestinal cancer cell lines as well as in 10 intestinal cancer tissues were verified by qPCR experiments. Results Through the bioinformatics analysis of multiple databases and preliminary experimental studies, we found that the expression of TMUB1 was significantly increased in colon cancer tumors, and was correlated with the clinical N stage, pathological grade, lymphatic metastasis and BMI of colon cancer. TMUB1 may be involved in the regulation of the malignant progression of colon cancer. Meanwhile, patients with high expression of TMUB1 mRNA had worse OS and DSS, and TMUB1 expression was an independent prognostic factor for OS and DSS. It was further found that highly expressed TMUB1 tissues showed low levels of immune infiltration and stromal infiltration. Conclusion We reported the expression level of TMUB1 in colon cancer and analyzed its potential prognostic value in colon cancer through the bioinformatics analysis and preliminary experimental studies. The high expression of TMUB1 is a negative prognostic factor for colon cancer patients. TMUB1 may be a potential target for colon cancer.
Collapse
Affiliation(s)
- Yan Lu
- Guangdong Medical University, Dongguan, Guangdong Province, China
- GCP Center, Shunde Hospital, Southern Medical University (The First People’s Hospital of Shunde Foshan), Foshan, Guangdong Province, China
| | - Kang Wang
- Department of Gastrointestinal Surgery, Shunde Hospital, Southern Medical University (The First People’s Hospital of Shunde Foshan), Foshan, Guangdong Province, China
- The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China
| | - Yuanhong Peng
- Department of Gastrointestinal Surgery, Shunde Hospital, Southern Medical University (The First People’s Hospital of Shunde Foshan), Foshan, Guangdong Province, China
- The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China
| | - Jun Zhang
- Department of Gastrointestinal Surgery, Shunde Hospital, Southern Medical University (The First People’s Hospital of Shunde Foshan), Foshan, Guangdong Province, China
- The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China
| | - Qinuo Ju
- Guangdong Country Garden School, Foshan, Guangdong Province, China
| | - Qihuan Xu
- Department of Gastrointestinal Surgery, Shunde Hospital, Southern Medical University (The First People’s Hospital of Shunde Foshan), Foshan, Guangdong Province, China
- The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China
| | - Manzhao Ouyang
- Department of Gastrointestinal Surgery, Shunde Hospital, Southern Medical University (The First People’s Hospital of Shunde Foshan), Foshan, Guangdong Province, China
- The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China
| | - Zhiwei He
- Guangdong Medical University, Dongguan, Guangdong Province, China
| |
Collapse
|